3d53a59177c457f420adf30858f82fd0f3f556d12db0bb284f19bf1b561a74fc

CooperVision

- Toric and Multifocal

- Sphere, Other

CooperSurgical

- Office and Surgical

- Fertility

Total Revenue

0a82aa858407e039487cd93f4541b851d387acfc35a7b73506222ff9ccdc4297

| Metric [Unit: USD Million] | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 |
|----------------------------|---------|---------|---------|---------|---------|---------|---------|---------|
| **CooperVision (CVI) Total Revenue** | **561.8**  **[0000711404-22-000046_cooperq42022pressrelease.htm:0]**  | **581.3**  **[0000711404-23-000008_cooperq12023pressrelease.htm:0]**  | **589.3**  **[0000711404-23-000029_cooperq22023pressrelease.htm:0]**  | **630.2**  **[COO_3311210_0]**  | **622.9**  **[0000711404-23-000068_cooperq42023pressrelease.htm:0]**  | **621.5**  **[0000711404-24-000016_cooperq12024pressrelease.htm:0]**  | **635.9**  **[0000711404-24-000038_cooperq22024pressrelease.htm:0]**  | **675.6**  **[0000711404-24-000058_cooperq32024pressrelease.htm:0]**  |
| Toric and Multifocal | **248.4**  **[0000711404-22-000046_cooperq42022pressrelease.htm:0]**  | **261.6**  **[0000711404-23-000008_cooperq12023pressrelease.htm:0]**  | **280.4**  **[0000711404-23-000029_cooperq22023pressrelease.htm:0]**  | **296.5**  **[COO_3311210_0]**  | **295.9**  **[0000711404-23-000068_cooperq42023pressrelease.htm:0]**  | **297.3**  **[0000711404-24-000016_cooperq12024pressrelease.htm:0]**  | **310.3**  **[0000711404-24-000038_cooperq22024pressrelease.htm:0]**  | **326.4**  **[0000711404-24-000058_cooperq32024pressrelease.htm:0]**  |
| Sphere, Other | **313.4**  **[0000711404-22-000046_cooperq42022pressrelease.htm:0]**  | **319.7**  **[0000711404-23-000008_cooperq12023pressrelease.htm:0]**  | **308.9**  **[0000711404-23-000029_cooperq22023pressrelease.htm:0]**  | **333.7**  **[COO_3311210_0]**  | **327.0**  **[0000711404-23-000068_cooperq42023pressrelease.htm:0]**  | **324.2**  **[0000711404-24-000016_cooperq12024pressrelease.htm:0]**  | **325.6**  **[0000711404-24-000038_cooperq22024pressrelease.htm:0]**  | **349.2**  **[0000711404-24-000058_cooperq32024pressrelease.htm:0]**  |
| **CooperSurgical (CSI) Total Revenue** | **286.3**  **[0000711404-22-000046_cooperq42022pressrelease.htm:0]**  | **277.2**  **[0000711404-23-000008_cooperq12023pressrelease.htm:0]**  | **288.1**  **[0000711404-23-000029_cooperq22023pressrelease.htm:0]**  | **300.0**  **[COO_3311210_0]**  | **304.2**  **[0000711404-23-000068_cooperq42023pressrelease.htm:0]**  | **310.1**  **[0000711404-24-000016_cooperq12024pressrelease.htm:0]**  | **306.7**  **[0000711404-24-000038_cooperq22024pressrelease.htm:0]**  | **327.2**  **[0000711404-24-000058_cooperq32024pressrelease.htm:0]**  |
| Office and Surgical | **177.8**  **[0000711404-22-000046_cooperq42022pressrelease.htm:0]**  | **165.2**  **[0000711404-23-000008_cooperq12023pressrelease.htm:0]**  | **163.0**  **[0000711404-23-000029_cooperq22023pressrelease.htm:0]**  | **178.4**  **[COO_3311210_0]**  | **182.9**  **[0000711404-23-000068_cooperq42023pressrelease.htm:0]**  | **191.1**  **[0000711404-24-000016_cooperq12024pressrelease.htm:0]**  | **182.9**  **[0000711404-24-000038_cooperq22024pressrelease.htm:0]**  | **197.9**  **[0000711404-24-000058_cooperq32024pressrelease.htm:0]**  |
| Fertility | **108.5**  **[0000711404-22-000046_cooperq42022pressrelease.htm:0]**  | **112.0**  **[0000711404-23-000008_cooperq12023pressrelease.htm:0]**  | **125.1**  **[0000711404-23-000029_cooperq22023pressrelease.htm:0]**  | **121.6**  **[COO_3311210_0]**  | **121.3**  **[0000711404-23-000068_cooperq42023pressrelease.htm:0]**  | **119.0**  **[0000711404-24-000016_cooperq12024pressrelease.htm:0]**  | **123.8**  **[0000711404-24-000038_cooperq22024pressrelease.htm:0]**  | **129.3**  **[0000711404-24-000058_cooperq32024pressrelease.htm:0]**  |
| **Total Consolidated Revenue** | **848.1**  **[0000711404-22-000046_cooperq42022pressrelease.htm:0]**  | **858.0**  **[0000711404-23-000008_cooperq12023pressrelease.htm:0]**  | **877.4**  **[0000711404-23-000029_cooperq22023pressrelease.htm:0]**  | **930.2**  **[COO_3311210_0]**  | **927.1**  **[0000711404-23-000068_cooperq42023pressrelease.htm:0]**  | **931.6**  **[0000711404-24-000016_cooperq12024pressrelease.htm:0]**  | **942.6**  **[0000711404-24-000038_cooperq22024pressrelease.htm:0]**  | **1,002.8**  **[0000711404-24-000058_cooperq32024pressrelease.htm:0]**  |

a055d7995794db6518f6766eaf61e0839b4ccd3396c5bd1f84620095de44ac26

1e05ee229d337ffefbf596bfa20574a676eda29e4d84befdafb297b637483d14

The Cooper Companies, Inc. is a global medical device company operating through two main business segments: CooperVision and CooperSurgical. CooperVision focuses on the vision correction market, developing, manufacturing, and marketing a wide range of soft contact lenses, including products like the MiSight 1 day lens, which is FDA-approved for slowing myopia progression in children **[0000711404-23-000072_coo-20231031.htm:6]** **[0000711404-24-000044_formsd-ex101cmreportfy2023.htm:0]** **[0000711404-23-000072_coo-20231031.htm:117]** **[0000711404-24-000008_coo-20240202.htm:23]**. CooperSurgical specializes in fertility and women's health, offering products and services such as medical devices, fertility products, cryostorage services, and contraception solutions like the PARAGARD IUD **[0000711404-23-000072_coo-20231031.htm:6]** **[0000711404-23-000072_coo-20231031.htm:9]** **[0000711404-24-000008_coo-20240202.htm:23]**. The company continues to expand its market presence through strategic acquisitions and product innovations in both segments **[0000711404-23-000072_coo-20231031.htm:6]** **[0000711404-23-000072_coo-20231031.htm:9]** **[0000711404-24-000008_coo-20240202.htm:23]**.

1. **CooperVision** - Develops, manufactures, and markets a wide range of soft contact lenses, including spherical, toric, multifocal, and myopia management lenses.
   - **MiSight 1 day lens** - FDA-approved lens designed to slow myopia progression in children.
   - **MyDay** - A product line contributing significantly to the company's revenue.
   - **Biofinity** - Another key product line in the vision correction market.
2. **CooperSurgical** - Focuses on fertility and women's health, offering a diverse portfolio of products and services.
   - **Fertility Products** - Includes medical devices and cryostorage services.
   - **Contraception Solutions** - Features products like the PARAGARD IUD.

3758746f30d8b7da9e062e5aa93c913c458e44377550ebabe77cc7f611b0155b

| Metric [USD Million] | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 |
|----------------------|---------|---------|---------|---------|---------|---------|---------|---------|
| Americas             | **228.1**  **[0000711404-22-000046_cooperq42022pressrelease.htm:0]**  | **241.4**  **[0000711404-23-000008_cooperq12023pressrelease.htm:0]**  | **243.3**  **[COO_3253526_0]**  | **248.6**  **[0000711404-23-000040_cooperq32023pressrelease.htm:0]**  | **257.9**  **[0000711404-23-000068_cooperq42023pressrelease.htm:0]**  | **252.6**  **[0000711404-24-000016_cooperq12024pressrelease.htm:0]**  | **264.4**  **[0000711404-24-000038_cooperq22024pressrelease.htm:0]**  | **279.8**  **[0000711404-24-000058_cooperq32024pressrelease.htm:0]**  |
| EMEA                 | **204.2**  **[0000711404-22-000046_cooperq42022pressrelease.htm:0]**  | **214.4**  **[0000711404-23-000008_cooperq12023pressrelease.htm:0]**  | **210.0**  **[COO_3253526_0]**  | **242.2**  **[0000711404-23-000040_cooperq32023pressrelease.htm:0]**  | **225.0**  **[0000711404-23-000068_cooperq42023pressrelease.htm:0]**  | **238.2**  **[0000711404-24-000016_cooperq12024pressrelease.htm:0]**  | **237.0**  **[0000711404-24-000038_cooperq22024pressrelease.htm:0]**  | **256.5**  **[0000711404-24-000058_cooperq32024pressrelease.htm:0]**  |
| Asia Pacific         | **129.5**  **[0000711404-22-000046_cooperq42022pressrelease.htm:0]**  | **125.5**  **[0000711404-23-000008_cooperq12023pressrelease.htm:0]**  | **136.0**  **[COO_3253526_0]**  | **139.4**  **[0000711404-23-000040_cooperq32023pressrelease.htm:0]**  | **140.0**  **[0000711404-23-000068_cooperq42023pressrelease.htm:0]**  | **130.7**  **[0000711404-24-000016_cooperq12024pressrelease.htm:0]**  | **134.5**  **[0000711404-24-000038_cooperq22024pressrelease.htm:0]**  | **139.3**  **[0000711404-24-000058_cooperq32024pressrelease.htm:0]**  |
| Total Revenue        | **561.8**  **[0000711404-22-000046_cooperq42022pressrelease.htm:0]**  | **581.3**  **[0000711404-23-000008_cooperq12023pressrelease.htm:0]**  | **589.3**  **[COO_3253526_0]**  | **630.2**  **[0000711404-23-000040_cooperq32023pressrelease.htm:0]**  | **622.9**  **[0000711404-23-000068_cooperq42023pressrelease.htm:0]**  | **621.5**  **[0000711404-24-000016_cooperq12024pressrelease.htm:0]**  | **635.9**  **[0000711404-24-000038_cooperq22024pressrelease.htm:0]**  | **675.6**  **[0000711404-24-000058_cooperq32024pressrelease.htm:0]**  |

2655fa11dc95cd8a2c5137380eaf48ca624314c9739baaca01fc7a81e4ad33aa

bbb51981b23dbb9134986880b54031b821ab8d0b56a28d2f154b9fc880178c4d

1. Given the unexpected revenue softness at the end of Q4 and the potential impact of recent price increases, can you provide more detail on how your pricing strategy is affecting consumer buying behavior and what measures you're taking to mitigate any potential negative effects on revenues?

2. With competitors accelerating their product launches and expanding their portfolios, how confident are you in your current pipeline and global launch strategy to maintain and grow your market share, and can you elaborate on specific new products or innovations that will differentiate you in fiscal 2025?

3. You mentioned that CooperSurgical faced challenges with the Q2 IT system upgrade that impacted operations; can you discuss how these issues affected your financial performance and operational efficiency, and what steps have been implemented to prevent similar disruptions in the future?

4. Considering that the recent acquisitions contributing approximately $25 million in annualized revenue are now part of the organic base and the M&A environment is currently quiet, how do you plan to drive growth organically in fiscal 2025, and what strategies are in place to compensate for the reduced contribution from acquisitions?

5. While you've indicated minimal exposure to tariffs from manufacturing in China, Mexico, or Canada, how are you assessing and mitigating potential supply chain and geopolitical risks in other regions where you have manufacturing facilities to ensure uninterrupted operations and protect your margins?

783e19560553147799e3a0573ef3d7ad2a60a28a1bb6c8268f2f6fc4525fc799

United States

Europe

Rest of World

Americas

- EMEA

- Asia Pacific

9151e9948711d3ac540b2acdfa72f20009020c495ee8f68396472e24637c20a6

- **Johnson & Johnson Vision Care, Inc.** - Competitor in the worldwide contact lens market, particularly in the spherical, toric, and multifocal lens categories  **[0000711404-24-000074_coo-20241031.htm:10]** .
- **Alcon Inc.** - Competitor in the worldwide contact lens market, particularly in the spherical, toric, and multifocal lens categories  **[0000711404-24-000074_coo-20241031.htm:10]** .
- **Bausch + Lomb** - Competitor in the worldwide contact lens market, particularly in the spherical, toric, and multifocal lens categories  **[0000711404-24-000074_coo-20241031.htm:10]** .
- **Vitrolife Group** - Competitor in the fertility market  **[0000711404-24-000074_coo-20241031.htm:10]** .
- **FujiFilm-Irvine Scientific** - Competitor in the fertility market  **[0000711404-24-000074_coo-20241031.htm:10]** .
- **Hamilton Thorne** - Competitor in the fertility market  **[0000711404-24-000074_coo-20241031.htm:10]** .
- **Fairfax Cryobank and Fairfax EggBank** - Competitors in the fertility market  **[0000711404-24-000074_coo-20241031.htm:10]** .
- **ViaCord, a division of Revvity** - Competitor in the stem cell storage field in the United States  **[0000711404-24-000074_coo-20241031.htm:10]** .
- **Bayer** - Competitor with hormonal IUDs  **[0000711404-24-000074_coo-20241031.htm:10]** .
- **AbbVie** - Competitor with hormonal IUDs  **[0000711404-24-000074_coo-20241031.htm:10]** .
- **Organon** - Competitor with Long Acting Reversible Contraceptives  **[0000711404-24-000074_coo-20241031.htm:10]** .
- **Medtronic** - Competitor with medical device products  **[0000711404-24-000074_coo-20241031.htm:10]** .
- **Hologic** - Competitor with medical device products  **[0000711404-24-000074_coo-20241031.htm:10]** .

0c036840ae7f6f19a82ea95e9e5cafac5ea160fd3a542f1c4fda948ad22ecf5c

Adjustments for Non-Cash Items (USD, millions)

Stock-Based Compensation (USD, millions)

Changes in Working Capital (USD, millions)

Capital Expenditures (CapEx) (USD, millions)

Proceeds from Debt (USD, millions)

Repayments of Debt (USD, millions)

Share Repurchases (USD, millions)

Dividend Payments (USD, millions)

Net Change in Cash (USD, millions)

4051fac6a0e1afc058db06e22135e82477403cadbd3453d8a95100366eada961

### Q4 2024 Earnings Call
- **Issued Period:** Q4 2024
- **Guided Period:** FY 2025
- **Guidance:**
  - **Revenue Guidance:**
    - **CooperVision:** $2.733 billion to $2.786 billion, up 6.5% to 8.5% organically  **[COO_3411001_4]** .
    - **CooperSurgical:** $1.347 billion to $1.372 billion, up 4% to 6% organically  **[COO_3411001_4]** .
    - **Consolidated Revenues:** $4.08 billion to $4.158 billion, up roughly 6% to 8% organically  **[COO_3411001_4]** .
  - **Operating Income Growth:** Expected to be roughly 10% to 12% in constant currency  **[COO_3411001_4]** .
  - **Interest Expense:** Expected to be roughly $90 million, assuming no interest rate changes by the Fed  **[COO_3411001_4]** .
  - **Effective Tax Rate:** Expected to be slightly over 15%  **[COO_3411001_4]** .
  - **Non-GAAP EPS:** Expected to be in the range of $3.92 to $4.02  **[COO_3411001_4]** .
  - **Currency Impact:** Expecting a headwind of roughly 1.5% to revenues and roughly 4% to earnings  **[COO_3411001_4]** .
  - **Free Cash Flow:** Expected to be in the range of $350 million to $400 million  **[COO_3411001_20]** .
  - **CapEx:** Expected to be around 11% of revenue, approximately $450 million  **[COO_3411001_20]** .

### Q3 2024 Earnings Call
- **Issued Period:** Q3 2024
- **Guided Period:** FY 2024
- **Guidance:**
  - **Consolidated Revenue:** $3.89 billion to $3.91 billion, representing an increase of 8% to 8.5% organically  **[COO_3400054_4]** .
  - **CooperVision Revenue:** $2.61 billion to $2.62 billion, representing an increase of 9% to 9.5% organically  **[COO_3400054_4]** .
  - **CooperSurgical Revenue:** $1.286 billion to $1.294 billion, representing an increase of 5.5% to 6.5% organically  **[COO_3400054_4]** .
  - **Interest Expense:** Expected to be roughly $109 million, assuming no interest rate changes by the Federal Reserve for the remainder of the fiscal year  **[COO_3400054_4]** .
  - **Effective Tax Rate:** Expected to be slightly over 14%  **[COO_3400054_4]** .
  - **Non-GAAP EPS:** Expected to be in the range of $3.64 to $3.67, representing an increase of 14% to 15%  **[COO_3400054_4]** .
  - **Fiscal Q4 Expectations:**
    - **CooperVision Growth:** Expected to grow 8% to 10% organically  **[COO_3400054_4]** .
    - **CooperSurgical Growth:** Expected to grow 6% to 8% organically  **[COO_3400054_4]** .
    - **Non-GAAP EPS:** Expected to be in the range of $0.98 to $1.01  **[COO_3400054_4]** .

### Q2 2024 Earnings Call
- **Issued Period:** Q2 2024
- **Guided Period:** FY 2024
- **Guidance:**
  - **Full Year Revenue Guidance:**
    - Consolidated revenues: $3.86 billion to $3.9 billion, up 7.5% to 8.5% organically  **[COO_3391183_4]** .
    - CooperVision revenues: $2.59 billion to $2.61 billion, up 8.5% to 9.5% organically  **[COO_3391183_4]** .
    - CooperSurgical revenues: $1.27 billion to $1.29 billion, with organic revenue growth unchanged at 5% to 7%  **[COO_3391183_4]** .
  - **Interest Expense:** Expected to be roughly $108 million, assuming no interest rate changes for the remainder of the fiscal year  **[COO_3391183_4]** .
  - **Effective Tax Rate:** Forecasted full-year effective tax rate of 14%  **[COO_3391183_4]** .
  - **Non-GAAP EPS Guidance:** Expected to be in the range of $3.54 to $3.60, up 11% to 13%  **[COO_3391183_4]** .
  - **Currency Impact:** The impact from foreign exchange (FX) is expected to be roughly $0.02 worse in the back half of the year compared to the previous quarter's guidance  **[COO_3391183_4]** .
  - **Quarterly EPS Expectation:** Non-GAAP EPS is anticipated to be higher in Q4 than in Q3  **[COO_3391183_4]** .

### Q1 2024 Earnings Call
- **Issued Period:** Q1 2024
- **Guided Period:** FY 2024
- **Guidance:**
  - **Full Year Consolidated Revenues:** $3.85 billion to $3.9 billion, representing an organic growth of 7% to 8%  **[COO_3376003_4]** .
  - **CooperVision Revenue Guidance:** Organic revenue growth is expected to be 8% to 9%, equating to $2.57 billion to $2.6 billion  **[COO_3376003_4]** .
  - **CooperSurgical Revenue Guidance:** Organic revenue growth is expected to be 5% to 7%, equating to $1.27 billion to $1.29 billion  **[COO_3376003_4]** .
  - **Non-GAAP EPS Guidance:** Expected to be in the range of $3.50 to $3.58, representing a year-over-year increase of 9% to 12%, or 15% to 17% in constant currency  **[COO_3376003_4]** .
  - **Interest Expense:** Assumed to be roughly $108 million  **[COO_3376003_4]** .
  - **Effective Tax Rate:** Expected to be roughly 14.5%  **[COO_3376003_4]** .
  - **Currency Impact:** The full-year impact is expected to be roughly a negative 1% to revenues and a negative 5% to earnings  **[COO_3376003_4]** .

f913303a524f87d302e10b89ac5e91b32da9dc22042b892e7c2d786181485d7c

| Name                  | Position                                                     | Start Date       | Short Bio                                                                                                                                                                                                                                                                                                                                 |
|-----------------------|--------------------------------------------------------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Albert G. White III   | President & Chief Executive Officer                          | May 2018         | Albert G. White III has served as the **President & Chief Executive Officer** of The Cooper Companies, Inc. since **May 2018**. He previously held roles such as Chief Financial Officer and Executive Vice President and Chief Strategy Officer. Before joining Cooper, he was a Director with KeyBanc Capital Markets  **[0000711404-24-000008_coo-20240202.htm:61]** .                                                   |
| Daniel G. McBride     | Executive Vice President & Chief Operating Officer           | November 2013    | Daniel G. McBride has served as the **Executive Vice President and Chief Operating Officer** since **November 2013**. He has held various roles within the company, including interim General Counsel and Secretary, and President of CooperVision. Before joining Cooper, he was an attorney with Latham & Watkins LLP  **[0000711404-24-000008_coo-20240202.htm:20]** **[0001193125-23-019077_d448199ddef14a.htm:18]** .                                                  |
| Brian G. Andrews      | Executive Vice President, Chief Financial Officer & Treasurer| December 2020    | Brian G. Andrews has served as **Executive Vice President, Chief Financial Officer & Treasurer** since **December 2020**. He has been with the company in various capacities since January 2013. Before joining Cooper, he held corporate and investment banking positions at KeyBanc Capital Markets and ING Barings  **[0000711404-24-000008_coo-20240202.htm:20]** **[0001193125-23-019077_d448199ddef14a.htm:19]** .                                                   |
| Agostino Ricupati     | Senior Vice President, Finance & Tax / Chief Accounting Officer | October 2017  | Agostino Ricupati has served as the **Senior Vice President, Finance & Tax / Chief Accounting Officer** since **October 2017**. Before joining Cooper, he was the International Tax Director at Intel Corp. and has over 20 years of experience in senior finance and tax roles  **[0000711404-24-000008_coo-20240202.htm:21]** **[0001193125-23-019077_d448199ddef14a.htm:20]** .                                                                                       |
| Nicholas S. Khadder   | Vice President, General Counsel & Corporate Secretary        | August 2022      | Nicholas S. Khadder has served as **Vice President, General Counsel & Secretary** since **August 2022**. Before joining Cooper, he was the general counsel of Standard BioTools, Inc. and held various positions at Amyris, Inc. He began his legal career as a corporate attorney at Fenwick & West LLP  **[0000711404-24-000008_coo-20240202.htm:21]** **[0001193125-23-019077_d448199ddef14a.htm:19]** .                                                              |
| Holly R. Sheffield    | President, CooperSurgical, Inc.                              | July 2020        | Holly R. Sheffield has served as the **President of CooperSurgical, Inc.** since **July 2020**. Before this role, she was the Executive Vice President & Chief Strategy Officer. She has over 20 years of experience in investment banking, including positions at UBS Securities LLC and Credit Suisse  **[0000711404-24-000008_coo-20240202.htm:21]** **[0001193125-23-019077_d448199ddef14a.htm:19]** .                                                               |
| Gerard H. Warner III  | President, CooperVision, Inc.                                | February 2022    | Gerard H. Warner III has served as the **President of CooperVision, Inc.** since **February 2022**. Prior to this role, he was the Executive Vice President, Americas & Global Commercial Functions of CooperVision. Before joining CooperVision, he spent 17 years at Bausch + Lomb in various marketing and management roles  **[0000711404-24-000008_coo-20240202.htm:21]** **[0001193125-23-019077_d448199ddef14a.htm:19]** .                                          |

83f8fa7b52d855e92cbb52679f62aefa2016e0b1d0680bf415943c9a4d61f5bb

| Program Details          | Program 1       |
|--------------------------|-----------------|
| Approval Date            | March 2017  **[0000711404-24-000074_coo-20241031.htm:105]** **[0000711404-24-000074_coo-20241031.htm:77]**  |
| End Date/Duration        | N/A             |
| Total Additional Amount  | **$1.0 billion**  **[0000711404-24-000074_coo-20241031.htm:105]** **[0000711404-24-000074_coo-20241031.htm:77]**  |
| Remaining Authorization  | **$256.4 million**  **[0000711404-24-000074_coo-20241031.htm:105]** **[0000711404-24-000074_coo-20241031.htm:77]**  |
| Details                  | The 2012 Share Repurchase Program was amended in March 2017 to increase the authorization to $1.0 billion. The program allows repurchases as permitted by securities laws and has no expiration date.  **[0000711404-22-000030_coo-20220430.htm:42]** **[0000711404-22-000042_coo-20220731.htm:43]** **[0000711404-23-000013_coo-20230131.htm:20]** **[0000711404-22-000042_coo-20220731.htm:20]** **[0000711404-22-000053_coo-20221031.htm:138]** **[0000711404-22-000030_coo-20220430.htm:18]** **[0000711404-23-000013_coo-20230131.htm:9]** **[0000711404-23-000045_coo-20230731.htm:10]** **[0000711404-23-000013_coo-20230131.htm:28]** **[0000711404-22-000042_coo-20220731.htm:51]**  |

84046124a338ce6e54ca7a5568b6f680b71b9b331bcb1345c03e31033df9f57b

**Annual guidance for FY 2025:**
- **Consolidated Revenues**: $4.08B to $4.158B  **[COO_3411001_4]**  (raised from $3.89B to $3.91B  **[COO_3400054_4]** )  
- **CooperVision Revenue**: $2.733B to $2.786B  **[COO_3411001_4]**  (raised from $2.61B to $2.62B  **[COO_3400054_4]** )  
- **CooperSurgical Revenue**: $1.347B to $1.372B  **[COO_3411001_4]**  (raised from $1.286B to $1.294B  **[COO_3400054_4]** )  
- **Operating Income Growth**: 10% to 12%  **[COO_3411001_4]**  (no prior guidance)  
- **Interest Expense**: $90M  **[COO_3411001_4]**  (lowered from $109M  **[COO_3400054_4]** )  
- **Effective Tax Rate**: slightly over 15%  **[COO_3411001_4]**  (raised from slightly over 14%  **[COO_3400054_4]** )  
- **Non-GAAP EPS**: $3.92 to $4.02  **[COO_3411001_4]**  (raised from $3.64 to $3.67  **[COO_3400054_4]** )  
- **Currency Impact**: ~1.5% headwind to revenues and ~4% headwind to earnings  **[COO_3411001_4]**  (no prior guidance)  
- **Free Cash Flow**: $350M to $400M  **[COO_3411001_20]**  (no prior guidance)  
- **CapEx**: approximately $450M  **[COO_3411001_20]**  (no prior guidance)  

896b51cb1d98dcf93cb82746063abfa08d0cf680f8a976ade1b7fa7b7a56d6f8

- COO is effectively leveraging prior investments in distribution and IT infrastructure, resulting in improved operating and gross margins, and expects to continue driving better free cash flow and profitability. [\[1\], \[5\], \[8\], \[12\]]
- CooperVision is experiencing strong and durable growth in the EMEA region, with revenue growth of **14%**, and anticipates maintaining strong performance due to great products and a successful team. [\[6\]]
- Increasing capacity and ongoing investments in capital expenditures and R&D are enabling COO to meet high demand, launch new products, and support future growth, particularly in the MyDay product line and CooperSurgical division. [\[11\], \[13\]]

50777bc52e70cc2087add13889e6cfdc937f6a768b25d645e6b8542a6604e4e2

| Name       | Start Date | End Date | Reason for Change |
|------------|------------|----------|-------------------|
| KPMG LLP   | 1982  **[0000711404-24-000074_coo-20241031.htm:83]**    | Present  | Current auditor   |

89951ab39f3e05241e36defcfcf4c788aed2eeae451150d0919fd5fddea721dc

c6c77165aea2f9471087b7b9698af2ac2d671e22cd96e1a17ae25855e51e8ebf

23794d91c53ae875c8e247d72561e35d9d06ee07c70c9e0dbcc977a6d161504a

- Total Revenue: $1,018.4 million (+10% YoY)  **[0000711404-23-000072_coo-20231031.htm:118]** **[0000711404-24-000074_coo-20241031.htm:112]** **[0000711404-24-000074_coo-20241031.htm:84]**   
- CooperVision: $676.4 million (+9% YoY)  **[0000711404-23-000072_coo-20231031.htm:118]** **[0000711404-24-000074_coo-20241031.htm:112]** **[0000711404-24-000074_coo-20241031.htm:111]**   
- CooperSurgical: $342 million (**+12%** YoY)  **[0000711404-23-000072_coo-20231031.htm:118]** **[0000711404-24-000074_coo-20241031.htm:112]** **[0000711404-24-000074_coo-20241031.htm:111]**   
- United States: $505.3 million (+7% YoY)  **[0000711404-23-000072_coo-20231031.htm:118]** **[0000711404-24-000074_coo-20241031.htm:112]**   
- Europe: $305.6 million (**+16%** YoY)  **[0000711404-23-000072_coo-20231031.htm:118]** **[0000711404-24-000074_coo-20241031.htm:112]**   
- Rest of World: $207.5 million (+8% YoY)  **[0000711404-23-000072_coo-20231031.htm:118]** **[0000711404-24-000074_coo-20241031.htm:112]**   
- Net Income: $117.5 million (**+39%** YoY)  **[0000711404-24-000074_coo-20241031.htm:84]** **[0000711404-23-000072_coo-20231031.htm:90]**   
- EPS (Diluted): $0.59 (**-65%** YoY)  **[0000711404-24-000074_coo-20241031.htm:84]** **[0000711404-23-000072_coo-20231031.htm:90]**   

818e99a23ac1d11794bf1a5211e4c287b421362e5d12d14ca70748ccca6257b7

885dbba16d81cb3477e0ad8380ca0fc64fe6f49e17b1c9fd1420b7b898d3323b

| Year  | Amount Due (in billions) | Debt Type                  | Interest Rate (%) | % of Total Debt                                                                 |
|-------|--------------------------|----------------------------|-------------------|---------------------------------------------------------------------------------|
| 2024  | 0.033                   | Short-term Debt            | N/A               | 1.3% = (0.033 / 2.5837) * 100 **[0000711404-24-000074_coo-20241031.htm:101]** **[0000711404-24-000074_coo-20241031.htm:86]**                                   |
| 2026  | 1.5                     | 2021 Term Loan Facility    | 5.94              | 58.1% = (1.5 / 2.5837) * 100 **[0000711404-24-000074_coo-20241031.htm:101]** **[0000711404-24-000074_coo-20241031.htm:102]**                                   |
| 2029  | 1.049                   | 2024 Revolving Credit Facility | 6.05              | 40.6% = (1.049 / 2.5837) * 100 **[0000711404-24-000074_coo-20241031.htm:101]** **[0000711404-24-000074_coo-20241031.htm:77]**                                 |

debced386d52df37f0aa0e5eace63772e3715e92eb21b85619b5b13c9ca80f7d

1. **Margins and Profitability Outlook**  
   **Q:** How will margins and profitability look in FY 2025?  
   **A:** Management expects **gross margin expansion** driven by **price increases**, better **freight costs**, and improved **manufacturing productivity**.  **[COO_3411001_12]**  They are committed to **operating margin expansion** with **10%-12% constant currency operating income growth**.  **[COO_3411001_12]** 

2. **FY 2025 Guidance**  
   **Q:** What is the growth outlook and guidance for FY 2025?  
   **A:** The company guides for **6.5%-8.5% growth** in CooperVision, continuing to grow faster than the market.  **[COO_3411001_6]**  They expect to outperform their guidance, as usual.  **[COO_3411001_28]** 

3. **Supply Constraints and Capacity Expansion**  
   **Q:** When will MyDay supply constraints improve?  
   **A:** Supply remains tight due to strong demand exceeding capacity. They are adding manufacturing lines but it takes time; they expect improvements through the year and into fiscal **2026** and **2027**.  **[COO_3411001_6]** **[COO_3411001_10]** 

4. **Market Softness in October**  
   **Q:** What caused the unexpected softness at quarter-end?  
   **A:** There was unexpected softness in the **U.S.** and **China** from mid-October into early November, possibly due to hurricanes, but things have now returned to normal.  **[COO_3411001_5]** 

5. **Competition and Market Share**  
   **Q:** How confident are you in outperforming the market in 2025?  
   **A:** Management remains confident in growing faster than the market, expecting to continue taking share despite increased competition.  **[COO_3411001_9]** 

6. **Pricing Environment and Inflation**  
   **Q:** Will the favorable pricing environment continue?  
   **A:** The contact lens industry will offset inflation impacts with price increases, expecting pricing to offset inflation around **2.5%-3%**, and this trend is expected to continue.  **[COO_3411001_14]** 

7. **MiSight Growth and Inventory Adjustments**  
   **Q:** What's the outlook for MiSight growth and recent inventory changes?  
   **A:** MiSight is expected to grow around **40%** in FY 2025, driven by markets worldwide.  **[COO_3411001_22]**  Recent inventory tightening by distributors caused some fluctuations, but overall growth remains strong.  **[COO_3411001_28]** 

8. **Paragard Performance and Competition**  
   **Q:** What's impacting Paragard's recent performance and outlook?  
   **A:** Paragard revenue was down **10%** in Q4, with expectations of flat to slightly down performance in FY 2025 due to competitive pressures.  **[COO_3411001_7]** **[COO_3411001_24]**  A new competitive product has not been approved yet.  **[COO_3411001_24]** 

9. **Fertility Business Growth**  
   **Q:** How is the fertility business performing and expected to grow?  
   **A:** The fertility business showed strong growth across consumables, genomics, donor activity, and capital equipment.  **[COO_3411001_19]**  The market is expected to grow **mid-single digits**, with the company aiming for **high single-digit growth**, supported by favorable trends and potential positive impact from the incoming administration.  **[COO_3411001_24]** 

10. **Tariff Exposure and Manufacturing Locations**  
    **Q:** What's the exposure to potential tariffs and manufacturing locations?  
    **A:** They have **no manufacturing** in **China**, **Mexico**, or **Canada**, so potential tariffs from the new administration are expected to have minimal impact.  **[COO_3411001_13]** 

11. **FX Headwinds**  
    **Q:** How will FX headwinds impact financials in FY 2025?  
    **A:** FX creates a **1.5% headwind to revenues** and **4% headwind to EPS**, impacting revenues evenly throughout the year.  **[COO_3411001_21]** 

12. **M&A Environment**  
    **Q:** Do you expect to continue being active in M&A?  
    **A:** The M&A environment is currently **very quiet**, and while previous acquisitions are performing well, they do not anticipate significant M&A activity in the near term.  **[COO_3411001_15]** 

e913bed55dd3aacf866770f515a16e54ae64d7dd89f44b27abf6b59c1ee439ed

- The company experienced **unexpected softness** in the U.S. and China markets during the fourth fiscal quarter, which **persisted into November**, potentially indicating slowing demand.  **[COO_3411001_5]**
- **Paragard sales declined 10%** in Q4 due to competitive pressures, and the company expects continued challenges with potential **flat or slightly negative growth** in fiscal 2025.  **[COO_3411001_7]**
- **Inventory contraction** in MiSight, the company's myopia management product, due to distributors tightening inventory, may lead to fluctuations and **volatility in sales**.  **[COO_3411001_28]**

fc7a7a452ea18461083a678078af376ef0d145e6b1459817e935bc14ccd10e0c

1. **Maintaining Growth Despite Tougher Comps**  
   **Q:** How will you sustain growth despite tougher comps?  
   **A:** We're optimistic about delivering strong growth in the back half of the year despite harder comps because of good momentum and improving capacity. We've faced capacity constraints in certain products, but as challenges reduce and new lines come online, we're able to meet the demand, which exceeds supply.  **[COO_3391183_5]** 

2. **Distribution Center Impact on Future Sales**  
   **Q:** Are distribution issues causing sales to be pushed or lost?  
   **A:** Most of the impacted sales are pushed rather than lost. An IT-related upgrade caused shipping delays, but we are addressing the backlog and proceeding better now. We don't see this issue extending over multiple quarters.  **[COO_3391183_6]** **[COO_3391183_12]** 

3. **Capacity Constraints and Expansion Plans**  
   **Q:** How are you addressing capacity constraints?  
   **A:** We're investing heavily in manufacturing equipment to expand capacity, especially for our MyDay products. Demand exceeds supply, but new state-of-the-art production lines are helping us meet demand. We expect capacity challenges to be a part of the industry for many years, but we are bringing additional lines online to meet demand.  **[COO_3391183_5]** **[COO_3391183_9]** **[COO_3391183_16]** 

4. **Operating Margin Improvements**  
   **Q:** What factors are driving operating margin expansion?  
   **A:** The leverage from investments in distribution centers, manufacturing, and IT is starting to materialize. We're seeing improvements in costs and efficiency, which is leading to **operating margin expansion**. We're in early stages of leveraging these investments and expect to continue delivering margin improvements.  **[COO_3391183_14]** **[COO_3391183_17]** **[COO_3391183_19]** 

5. **EMEA Performance Sustainability**  
   **Q:** Can you sustain strong growth in EMEA?  
   **A:** Our EMEA team has been performing exceptionally, driven by key account wins, geographic expansion, and meeting demand with new products. While it may be difficult to maintain the current high growth levels quarter after quarter, we anticipate continued strong performance in the region.  **[COO_3391183_15]** **[COO_3391183_18]** **[COO_3391183_20]** 

6. **China Weakness and Recovery Expectations**  
   **Q:** What's causing weakness in China, and what's the outlook?  
   **A:** The weakness in ortho-k sales is driven by China, which pulls down our Asia Pac numbers. We need stability in that market, but we expect ortho-k to start growing in Q3 and see better footing in the back half of the year.  **[COO_3391183_22]** 

7. **PARAGARD Expectations and Competitive Impact**  
   **Q:** What are your expectations for PARAGARD sales?  
   **A:** We expect PARAGARD sales to be **negative in Q3**, offsetting a strong Q2 due to lumpiness from inventory and pricing dynamics. Full-year growth is expected to be **flat to slightly up**. There's potential competition from a low copper IUD under FDA review, but we don't know when it will be approved.  **[COO_3391183_12]** **[COO_3391183_19]** **[COO_3391183_21]** **[COO_3391183_23]** **[COO_3391183_24]** 

8. **MiSight Progress and Competition**  
   **Q:** How is MiSight performing and what's the competitive landscape?  
   **A:** We're seeing increased activity globally with more fitters and higher fitting rates among existing practitioners. MiSight is still the only FDA-approved product for myopia control, and as of today, there's no competition other than off-label use of other products.  **[COO_3391183_8]** 

9. **Contact Lens Pricing Assumptions**  
   **Q:** What are your assumptions for contact lens pricing?  
   **A:** We've seen almost everyone take price increases earlier this year, and pricing is holding steady. About **one-third** of market growth, which is **mid to upper single digits**, is coming from price.  **[COO_3391183_7]** 

10. **Inventory Levels and Impact**  
    **Q:** Any concerns about changes in inventory levels?  
    **A:** Inventory levels are a bit tighter as customers reduce inventory due to higher interest rates. However, we've already worked through most of this, and we don't see any real risk associated with inventory contraction.  **[COO_3391183_10]** **[COO_3391183_11]** 

11. **CapEx and R&D Investments**  
    **Q:** What are your focus areas for organic investment?  
    **A:** We're investing significantly in capital expenditures to expand manufacturing capacity, especially for MyDay products. We also have exciting R&D projects within CooperSurgical and MiSight, although we can't share specifics yet.  **[COO_3391183_9]** **[COO_3391183_16]** 

12. **Capital Allocation Plans**  
    **Q:** How are you thinking about capital allocation?  
    **A:** Our priority is organic investments, which offer higher returns and lower risk. We're also paying down debt, and we're open to evaluating acquisitions if opportunities arise that make sense.  **[COO_3391183_20]** 

13. **Tax Rate Guidance**  
    **Q:** What's driving changes in your tax rate outlook?  
    **A:** The lower effective tax rate is due to stock option exercises, which are hard to forecast. Our underlying organic tax rate is around **15% to 15.5%**, and we expect that to be the starting point for next year.  **[COO_3391183_19]** 

14. **Free Cash Flow Expectations**  
    **Q:** What's your outlook for free cash flow?  
    **A:** We expect free cash flow to be about **$100 million** higher than last year. While taxes, interest, and FX are headwinds, we're doing the right things to drive higher free cash flow, and CapEx investments are for the right reasons.  **[COO_3391183_24]** 

0f0d9d9e6d73472b3d9ff1512ca63484068c18f28cf008464da3aa8c5225b065

1. **Fiscal 2025 Outlook**  
   **Q:** Will OI growth lead to higher EPS in '25?  
   **A:** Management affirmed their goal of **low double-digit** constant currency operating income growth for fiscal 2025  **[COO_3400054_10]** ,.  **[COO_3400054_14]**  Stronger free cash flow will allow for debt reduction, lowering interest expenses  **[COO_3400054_10]** ,.  **[COO_3400054_14]**  FX is currently a positive, and while the effective tax rate will be higher next year (above **15.5%** this year), overall this should result in decent EPS growth  **[COO_3400054_10]** ,.  **[COO_3400054_14]** 

2. **Capacity Expansion**  
   **Q:** Are capacity constraints being resolved to meet demand?  
   **A:** Demand still exceeds supply, especially for the **MyDay** product line  **[COO_3400054_8]** ,  **[COO_3400054_12]** ,.  **[COO_3400054_23]**  The company is bringing capacity online, improving their ability to meet demand and enabling incremental launch activities  **[COO_3400054_8]** ,.  **[COO_3400054_23]**  This progress makes them optimistic about future growth as they expand capabilities  **[COO_3400054_8]** ,.  **[COO_3400054_23]** 

3. **Market Conditions**  
   **Q:** Is the contact lens market softening?  
   **A:** The market remains healthy globally and in the U.S..  **[COO_3400054_6]**  Despite occasional noise like consumer rebates, the market shows continued growth, especially in mid- and higher-end products like **torics** and **multifocals**.  **[COO_3400054_6]** 

4. **Pricing Outlook**  
   **Q:** How are you approaching pricing in fiscal '25?  
   **A:** The company plans to raise prices again in fiscal Q1 to offset inflation  **[COO_3400054_10]** ,.  **[COO_3400054_16]**  With inflation around **3%**, they expect industry price increases in the **2–3%** range to support market growth  **[COO_3400054_10]** ,.  **[COO_3400054_16]** 

5. **Margin Maintenance**  
   **Q:** How are you maintaining strong margins?  
   **A:** Price and efficiency gains are offsetting FX headwinds.  **[COO_3400054_15]**  Improvements in intercompany shipping and infrastructure have enhanced gross margins.  **[COO_3400054_15]**  While dailies are a headwind, continuous improvement activities will help increase gross margins over time.  **[COO_3400054_15]** 

6. **Myopia Management Growth**  
   **Q:** What's driving growth in myopia management?  
   **A:** Myopia management generated about **$37 million** this quarter, with **MiSight** now larger than ortho-K  **[COO_3400054_13]** ,.  **[COO_3400054_22]**  Adoption is in early stages, but global interest is growing  **[COO_3400054_13]** ,.  **[COO_3400054_22]**  Anticipated FDA approval of spectacles could significantly expand the market  **[COO_3400054_13]** ,.  **[COO_3400054_22]** 

7. **PARAGARD Outlook**  
   **Q:** What's the outlook for PARAGARD amid competition?  
   **A:** PARAGARD is expected to be slightly up this year  **[COO_3400054_24]** , despite a declining IUD market.  **[COO_3400054_20]**  The new single-hand inserter improves practitioner efficiency, putting PARAGARD on par with competitors  **[COO_3400054_18]** ,.  **[COO_3400054_23]**  Management is confident due to its unique **10-year** indication and strong market position.  **[COO_3400054_18]** 

8. **APAC Growth**  
   **Q:** Why was APAC growth softer?  
   **A:** APAC sales were softer due to supply constraints; more product is needed to meet demand.  **[COO_3400054_12]**  The company is working to bring more capacity online, particularly for **MyDay**, to support regional growth.  **[COO_3400054_12]** 

9. **Operating Expense Leverage**  
   **Q:** What drove SG&A leverage this quarter?  
   **A:** Both businesses executed well, achieving meaningful SG&A leverage.  **[COO_3400054_9]**  Investments over recent years are yielding efficiencies and positive returns.  **[COO_3400054_9]**  This trend is expected to continue into next quarter and beyond.  **[COO_3400054_9]** 

10. **Competitive Position**  
    **Q:** Are you concerned about competitors reclaiming share?  
    **A:** Management is not worried about competitors reversing decisions like reinstating toric SKUs.  **[COO_3400054_17]**  They believe their market-leading toric products retain patients.  **[COO_3400054_17]**  Their consistent performance is due to a broad portfolio and strong products across segments.  **[COO_3400054_21]** 

11. **Distributor Issue Impact**  
    **Q:** Did last quarter's distributor issue affect sales?  
    **A:** The CooperSurgical IT upgrade issue disrupted sales slightly into this quarter but has been resolved.  **[COO_3400054_11]**  A residual upside is expected in Q4, with CooperSurgical growth guided at **6–8%**.  **[COO_3400054_11]** 

90044f78c57639a7ecbad84c2e014a06724fdbbd3931b21519dc888cb337d5d2

- **Cooper Companies is facing challenges in the Chinese market for its myopia management products**, with the CEO admitting that China is "**a market where we struggle**," limiting growth potential in a significant market.  **[COO_3400054_23]**
- **The company is dealing with potential litigation** from a culture media recall in its fertility business, which could **pose financial risks despite having insurance coverage**.  **[COO_3400054_7]**
- **An expected increase in the effective tax rate year-over-year** may impact earnings per share growth in fiscal 2025.  **[COO_3400054_15]**

5543ebb8f0a7aaf7cfaecc648ec49d788f48cbe3c8c2df122ddb9c1db0c901a5

- **MiSight shows strong underlying demand** with **strong back-to-school fits**, indicating robust growth potential despite temporary inventory adjustments by distributors.  **[COO_3411001_28]**
- The **company is confident in delivering strong results in fiscal '25** and has a history of **outperforming guidance**, signaling strong management and growth prospects.  **[COO_3411001_28]**
- Management demonstrates **transparency and proactive management** in addressing inventory fluctuations, suggesting they are well-prepared to handle short-term challenges and maintain growth momentum.  **[COO_3411001_28]**

a591f4538c86f71485da43a8dda86f1106e827c684502313a5e05914ee7ae4b9

- **Free cash flow is under pressure due to higher CapEx spending and headwinds from taxes, interest, and foreign exchange.** Despite expecting free cash flow to be about $100 million higher than last year, the first half was behind prior years, and CapEx will be high again this year due to capacity expansion.  **[COO_3391183_30]**
- **Weakness in the Ortho-K business in China is impacting growth in the Asia-Pacific region.** The Ortho-K sales were down in low single digits, pulling down Asia-Pacific numbers, with recovery depending on market stability in China.  **[COO_3391183_26]**
- **Operating margins have not returned to pre-COVID levels, remaining lower than the high 20% levels seen previously, with significant headwinds from foreign exchange.** FX has been a significant negative, and improvements depend on leveraging investments.  **[COO_3391183_27]**

b55c274852aaa06a166cbc55195b5a02feee5ad116db1c19d401cbe0108a3edf

- **Strong Operational Momentum with Expected Low Double-Digit Operating Income Growth:** The management emphasized their commitment to delivering low double-digit constant currency operating income growth for fiscal 2025, indicating strong operational momentum going into next year. They expect stronger free cash flow, allowing for debt repayment, and potential upside from positive foreign exchange impacts.  **[COO_3400054_10]**
- **Improving Gross Margins Through Pricing and Efficiency Gains:** Despite potential headwinds from expanding daily contact lens products, the company is successfully offsetting these with price increases and efficiency gains, particularly in intercompany shipping and infrastructure investments. This efficiency is contributing to improved gross margins, with expectations to continue increasing margins over the longer term.  **[COO_3400054_16]**
- **Positive Product Mix Shift Enhancing Long-Term Margins:** Growth in higher-margin products such as toric and multifocal lenses is driven by innovative offerings like Energys. This product mix shift is contributing to higher prices and improved operating margins over time, supporting long-term accretive benefits to the company's profitability.  **[COO_3400054_17]**

0c6910e6c2882f481f4f44105834396c53e02f28b0df26e9104badced44ea0e5

1. **Guidance Increase for CooperVision**  
   **Q:** What gives confidence to raise CooperVision growth guidance?  
   **A:** We achieved **7% growth** in Q1, almost reaching **8%**, and with improved capacity and strong February performance, we're confident in returning to **double-digit growth** starting in Q2. Thus, we're raising our guidance from **7%-9%** to **8%-9%**.  **[COO_3376003_10]** 

2. **Margin Outlook and FX Impact**  
   **Q:** How will gross and operating margins look for fiscal 2024?  
   **A:** Gross margins are expected to be similar to last year, depending on product mix. Operating margins should increase year-over-year. However, **FX will have a more negative impact in Q2 and Q3**, affecting margins.  **[COO_3376003_8]** 

3. **PARAGARD Competitive Risks**  
   **Q:** Is there concern about PARAGARD competition and growth slowing?  
   **A:** While underlying demand is a struggle, we anticipate PARAGARD to be roughly **flat year-over-year**. Potential generic competition hasn't materialized yet, so we're cautiously optimistic and have adjusted guidance from **4%-6%** to **5%-7%** growth for CooperSurgical.  **[COO_3376003_9]** **[COO_3376003_26]** 

4. **Contact Lens Market Growth**  
   **Q:** Do you still expect 5%-7% contact lens market growth?  
   **A:** Yes, we maintain the expectation of **5%-7%** market growth but lean toward the upper end due to strong fundamentals and ongoing transition to daily lenses.  **[COO_3376003_21]** 

5. **Capacity Constraints and Demand**  
   **Q:** How are capacity constraints affecting ability to meet demand?  
   **A:** Demand remains strong, and while we can't meet all of it yet, our improved capacity allows us to support existing customers and launch new products. **Additional capacity coming online positions us for strong years ahead**.  **[COO_3376003_6]** **[COO_3376003_14]** 

6. **Price Increases and Consumer Acceptance**  
   **Q:** How are price increases impacting growth and are consumers accepting?  
   **A:** We're seeing **low single-digit price increases**, around **2%-3%**, mostly through product mix shifts to higher-priced dailies. There's no significant pushback from consumers, and future price increases depend on the economy.  **[COO_3376003_6]** **[COO_3376003_25]** 

7. **Myopia Management Market Potential**  
   **Q:** What's the opportunity with MiSight and SightGlass in myopia management?  
   **A:** The myopia management market is large, potentially in the **billions of dollars**. Spectacles with SightGlass will become first-line therapy, especially for children, and MiSight contact lenses will serve those needing added convenience or better compliance. Together, they offer significant growth potential.  **[COO_3376003_13]** **[COO_3376003_22]** 

8. **Fertility Market Growth Continuation**  
   **Q:** Can fertility growth continue at double digits?  
   **A:** Yes, despite headlines, the global fertility market remains strong, and underlying characteristics support continued **double-digit growth** for years.  **[COO_3376003_7]** 

9. **Regional Performance Variances**  
   **Q:** Why was AsiaPac growth lower compared to Europe in CVI?  
   **A:** AsiaPac was impacted by capacity constraints, particularly in Japan, affecting product allocation. Europe performed strongly due to effective teams and product availability improvements.  **[COO_3376003_17]** **[COO_3376003_27]** 

10. **New Product Innovations**  
    **Q:** What are the plans for new product launches in silicone hydrogel lenses?  
    **A:** We continue to expand our MyDay family with recent launches like **MyDay Multifocal** and **MyDay Energys**. There's still work to bring these products to more markets, and future launch activity will focus on expanding existing products.  **[COO_3376003_29]** 

06249fcc4a0744a3944c02a35d32612960d1b519a11c9ef9515cfd132b1ade5e

- The company's PARAGARD product is experiencing underlying demand struggles and faces potential competition from a generic product that could impact sales if approved.  **[COO_3376003_26]**
- The SightGlass joint venture is generating losses reported below operating income, which continues to be a drag on earnings.  **[COO_3376003_12]**
- The consolidation of revenue reporting for CooperVision products, such as MiSight being reported under "sphere," may reduce transparency in product performance reporting.  **[COO_3376003_11]**

e297025a6fb54341c46f22f9d16f0a46cc67764e80d96254b04dc5879a9571ff

- Cooper Companies expects accelerated revenue growth in its CooperVision division, with the CEO expressing confidence in returning to **double-digit growth as early as Q2**, supported by **improved capacity to meet strong demand** for their contact lenses.  **[COO_3376003_9]** **[COO_3376003_5]**
- The company has **raised its full-year guidance** for both revenues and earnings, increasing CooperVision's organic revenue growth guidance to **8%-9%** and non-GAAP EPS guidance to **$3.50-$3.58**, reflecting strong business momentum.  **[COO_3376003_4]** **[COO_3376003_9]** **[COO_3376003_7]**
- The **myopia management market presents a significant growth opportunity** for Cooper Companies, with products like **MiSight and SightGlass** expected to drive future revenues in a market estimated to be worth **billions of dollars**.  **[COO_3376003_13]** **[COO_3376003_12]**

4a1118e64d527eb17274ec4119ce6e05033eded6bada9303b3a814e353aab403

Cooper Companies Inc (COO)

Financials